FDA wants social media giants to help crack down on illegal opioid marketers

FDA
The FDA crackdown on opioids continues with a new effort targeting online illegal sales and a push to bring tech companies to the table to talk about the problem. (FDA)

The FDA’s latest crackdown targets pharmacies hawking illegal opioids online. The agency issued warning letters this week to nine online pharmacies that run 53 websites selling drugs with suspect monikers like “Roxycodone” and “Tramadol Generic.”

Many of the websites shut down one day later, but at least one—OneStopPharma.org—was still operating Thursday morning.

While legitimate FDA-approved pharma opioid makers had long quit marketing to consumers and even doctors, the illegal online pill-pushing remains rampant. And the FDA is trying to enlist the online platforms that host or display ads from the fly-by-night pharmacies.

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

Facebook and Twitter are among the digital and social media companies FDA Commissioner Scott Gottlieb is pressuring for help. He has invited those companies, among others, to participate in its “FDA Online Opioid Summit” set for June 27.

RELATED: Citizen petition calls on FDA to pull powerful opioids from market

“The internet is virtually awash in illegal narcotics, and we’re going to be taking new steps to work with legitimate internet firms to voluntarily crack down on these sales,” Gottlieb said in a statement announcing the crackdown on online marketers. The summit is aimed at finding “new ways to work collaboratively” with the social and tech companies “to address these issues.”

Purdue Pharma quit marketing its opioid drug Oxycontin to doctors earlier this year, while other opioid makers—including Endo, Teva, Allergan and Johnson & Johnson’s Janssen unit—had all stopped marketing opioids before Purdue’s announcement, with some backing off several years ago.

Suggested Articles

With a deal for the digoxin portfolio of Poland's Nobilus, C2 Pharma will have two supplies of API for making the sometimes difficult-to-get drug.…

A North Carolina federal jury found that Puma maliciously defamed Eshelman amid a proxy fight that began in late 2015.

Merck KGaA says it will invest €1 billion in its headquarters site in Darmstadt, Germany, as part of a five-year agreement reached with workers there.